• 6559 Citations
  • 35 h-Index
1987 …2024
If you made any changes in Pure these will be visible here soon.

Personal profile


Professor Howard Gurney is the Director of Clinical Trials for the Faculty of Medicine and Health Sciences at Macquarie University. 

Professor Gurney has a firm background in clinical research and has subspecialty interests in urogenital cancers including prostate, bladder, testis and kidney cancer. 

He has been the principal investigator for over 100 clinical trials and has published over 100 peer-reviewed articles in journals and book chapters.  Current research interests include the pharmacogenomics and therapeutic monitoring of chemotherapy and targeted therapies and he has published widely in this area.  He is regarded as a leading authority on mechanisms for safe dosing of anticancer agents and has held research grants and has written a number of invited editorials on these topics. 

Fingerprint Dive into the research topics where Howard Gurney is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 6 Similar Profiles
Prostatic Neoplasms Medicine & Life Sciences
Renal Cell Carcinoma Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Drug Therapy Medicine & Life Sciences
Castration Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
docetaxel Medicine & Life Sciences
Survival Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 2013 2024

Research Outputs 1987 2019

Tamoxifen-induced severe hot flashes and endoxifen levels: is dose reduction a safe and effective strategy?

Lee, C. I., Fox, P., Balakrishnar, B., Balleine, R. L., Gao, B., Provan, P., Coulter, S., Liddle, C., Hui, R., Wong, M., Gurney, H. & Wilcken, N., 1 Aug 2019, In : Breast. 46, p. 52-57 6 p.

Research output: Contribution to journalArticleResearchpeer-review

Hot Flashes
Cytochrome P-450 CYP2D6

Abiraterone alone or in combination with enzalutamide in metastatic castration-resistant prostate cancer with rising prostate-specific antigen during enzalutamide treatment

Attard, G., Borre, M., Gurney, H., Loriot, Y., Andresen-Daniil, C., Kalleda, R., Pham, T., Taplin, M. E. & on behalf of PLATO collaborators, 1 Sep 2018, In : Journal of Clinical Oncology. 36, 25, p. 2639-2646 8 p.

Research output: Contribution to journalArticleResearchpeer-review

Open Access
Prostate-Specific Antigen
Prostatic Neoplasms
Control Groups

Cardiovascular toxicity of targeted therapies for cancer: a protocol for an overview of systematic reviews

Van Leeuwen, M. T., Luu, S., Gurney, H., Brown, M. R., Webber, K., Pearson, S-A., Hunt, L. & Vajdic, C. M., 1 Jun 2018, In : BMJ Open. 8, 6, p. 1-6 6 p., e021064.

Research output: Contribution to journalReview articleResearchpeer-review

Open Access
Embolism and Thrombosis
Cerebrovascular Disorders
Peer Review

Genome-wide association study of paclitaxel and carboplatin disposition in women with epithelial ovarian cancer

Gao, B., Lu, Y., Nieuweboer, A. J. M., Xu, H., Beesley, J., Boere, I., De Graan, A. J. M., De Bruijn, P., Gurney, H., Kennedy, C. J., Chiew, Y. E., Johnatty, S. E., Beale, P., Harrison, M., Luccarini, C., Conroy, D., Mathijssen, R. H. J., Harnett, P. R., Balleine, R. L., Chenevix-Trench, G. & 2 othersMacGregor, S. & De Fazio, A., 1 Dec 2018, In : Scientific Reports. 8, 1, p. 1-10 10 p., 1508.

Research output: Contribution to journalArticleResearchpeer-review

Open Access
Genome-Wide Association Study
Single Nucleotide Polymorphism
Drug Therapy